The pharmaceutical company Zoetis has partnered with the renowned Gluck Equine Research Center at the University of Kentucky to show that Fluvac Innovator, the first equine influenza virus (EIV) vaccine, can provide a demonstrated cross-reactive immune response against emerging EIV strains.

Their most recent study demonstrated an immune response against the Richmond 07 strain. Although Richmond 07 is not circulating in the United States, it might be a threat to horses with international exposure.

To help ensure vaccines offer current protection, the World Organization for Animal Health (OIE) encourages vaccine manufacturers to work with laboratories, such as the Gluck Center, that can test for reactivity against circulating strains.

With test studies against six EIV strains since 2002, Zoetis continues its legacy of evaluating the Fluvac Innovator line of vaccines to help ensure the most relevant protection